Please provide your email address to receive an email when new articles are posted on . Avacopan was associated with fewer serious adverse events than controls in ANCA-associated vasculitis. Data from ...
In this randomized, controlled trial, we assigned patients with ANCA-associated vasculitis in a 1:1 ratio to receive oral avacopan at a dose of 30 mg twice daily or oral prednisone on a tapering ...
The risk for major adverse cardiovascular events is a recognized, important complication reported among patients with ANCA-associated vasculitis. In patients with antineutrophil cytoplasmic antibody ...
ANCAs are mainly IgG in nature. These are specific autoantibodies. Thus they are antibodies produced by the immune system that mistakenly target the individual’s own proteins. They are directed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results